Conference Details - Overview
11th International Lung Cancer Congress
Terranea
Rancho Palos Verdes, CA
July 8-11, 2010
Conference Overview
Overview and Purpose
The purpose of the 11th International Lung Cancer Congress is to provide participants with an update on advances in the field of lung cancer, including biology, pathology, staging, personalized therapy, maintenance therapy, novel agents, and ongoing research in Cooperative Groups. Bringing key data from international oncology conferences to participants, the congress will emphasize the importance of personalized therapy and address other current topics of interest, such as maintenance therapy and novel targeted agents. State-of-the-art treatment for early-stage locally advanced and metastatic lung cancer will be discussed. In addition to non–small-cell lung cancer (NSCLC), the congress will address therapy for small-cell lung cancer (SCLC) and mesothelioma. A regular feature of the International Lung Cancer Congress is an update of research efforts from major Cooperative Groups from the United States, Europe, and Asia. The format of the meeting will include didactic lectures from internationally renowned leaders, debates and discussions on controversial topics, extensive panel discussions with case scenarios, multidisciplinary tumor boards, question-and-answer sessions, and afternoon translational workshops focusing on future strategies in development for the treatment of lung cancer.
Target Audience
This educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer are also invited to attend.
Learning Objectives
At the conclusion of this congress, you should be able to:
- Assess the changes in lung cancer staging with the IASLC Staging Project revisions to T and M definitions
- Summarize clinical data on the efficacy of adjuvant/neoadjuvant chemotherapy for patients with early-stage NSCLC
- Assess the role of biomarkers in molecular epidemiology in early-stage NSCLC
- Discuss the feasibility of sublobar resections in early-stage NSCLC
- Choose the appropriate therapy for patients with lung cancer based on biomarker status and tumor characteristics
- Evaluate the efficacy and toxicity of combined modality regimens in locally advanced lung cancer
- Describe approaches to improve treatment outcomes with first- and second-line therapies in advanced lung cancer
- Discuss the clinical benefits of maintenance therapy with cytotoxic and targeted agents in advanced NSCLC
- Summarize new approaches to deliver radiation therapy in lung cancer
- Personalize therapeutic approaches for patients with mesothelioma
- Describe current approaches to patients with limited- and extensive-disease SCLC
- Discuss clinical data on new targeted agents in development for lung cancer
- Summarize current research activity in lung cancer from national and regional Cooperative Groups
Meeting information is accurate at the time of posting.